Market Insight - Orphan drugs, multiple benefits
This article was originally published in Scrip
According to the US National Organization for Rare Disorders (NORD), 320 drugs were approved for orphan indications in the US during the 25 years since the US Orphan Drug Act (ODA) was passed in 1983. Of these, 177 were approved since 1995, while fewer than 10 were approved between 1973 and 1983.
You may also be interested in...
One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in India, where it hopes to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic firms, Abbott isn't about to get complacent, Michael Warmuth, senior VP of the company's Established Products Division, tells Pete Chan. This article is part of the 2011 Scrip Asia 100.
Asia life science-focused VC firms*
Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.